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group: 44% male, 56% female in the prior ipsilateral meniscal
procedure group as compared to 30% male, 67% female in the
no prior procedure group. Signiﬁcantly, more patients with a prior
meniscal procedure were under 60 years of age (40% v. 18%) and
were on average, 7 years younger than patients without a prior
procedure. Comparing the prior meniscal procedure group v. the
non- procedure group, no signiﬁcant differences were observed
in self-reported function (SF12 PCS = 31 v. 30); BMI (32 v. 32)
or emotional health (SF12 MCS =51 v. 52). Patients experiencing
pain levels in both the severe and moderate categories (PCS <30;
30-44) were signiﬁcantly higher in the prior procedure group v.
the non-prior procedure group (31% v. 26% and 25% v. 18%).
In addition, signiﬁcantly more patients had normal alignment in
the prior procedure group than non-prior procedure group (56% v.
50%).
Conclusions: The prevalence, incidence and burden of knee OA
in those with prior ipsilateral meniscal injuries are not known.
These analyses found a signiﬁcant percentage (20) of TKR pa-
tients with a prior ipsilateral meniscal procedure (APM or open).
When compared to TKR patients with no prior procedure, patients
with prior meniscal procedures are younger at surgery but expe-
rience levels of pain, functional limitation, and emotional health
comparable to the older TKR patients with no prior procedure. In
fact, the proportion of patients with severe disability (PCS <30)
was higher in the prior-procedure group than in the non- proce-
dure group (31% v. 26%). Additional research is needed to clarify
speciﬁc relationships between types of prior meniscal injuries and
types of repair procedures and estimates of the incidence of OA
in these younger patients. Taken together, current data suggest
the possibility of growing a public health problem in which younger
OA patients are more signiﬁcantly impaired perhaps due to soft
tissue knee injuries from more active lifestyles earlier in life. Since
TKR is not an immediate option in all cases, chondroprotective
pharmacologic research such as disease-modifying osteoarthritis
drug (DMOADs) development is desirable to meet these needs.
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Purpose: The IAGH method demonstrates the efﬁcacy, safety,
and low cost of a stem cell productive method of regenerating
articular cartilage in arthritic knees. This method provide a tissue
regenerative alternative to metal/plastic artiﬁcial joints and requires
no transplants. IAGH treatment costs 1/4 the cost of total joint
surgery and can save billions of dollars spent on medical care
annually.
Methods: Sixty-six patients with advanced osteo-arthritis of the
knee were treated with a series of intra-articular injections of
human growth hormone (HGH). One third of the patients required
arthroscopic surgery to remove torn menisci, avascular areas and
chondral ﬂaps. The dose of HGH varied from 5 mgm to 10 mgm
depending on the size of the joint. The length of treatment varied
from six to ten weeks depending on the response to treatment
as measured by increase in joint space. Standing X-rays were
taken pre-treatment, bi-weekly during treatment and at the end
of the study. The space between the femoral condyle and the
tibial plateau was carefully measured on every X-ray. The patients
were again examined from two to four (4) years post treatment.
Patients were evaluated for return of joint spaces, absence of pain,
increase of motion and return to normal activities (IKDC scales).
Results: Eighty-six per cent. (sixty)of the patients showed marked
improvement with increase of joint space, absence of pain, in-
crease of motion, and return to normal activities (IKDC scale). Of
the remaining six patients, only three had total knees and three
patients were undecided. Graphs and data are included. There
were no infections, complications or deaths associated with this
treatment.
Conclusions: A safe, efﬁcacious, economical and readily available
alternative to total joint surgery. This treatment can lower the cost
of medical care by billions of dollars annually. The beneﬁts of
IAGH treatment: There are no complications, infections or deaths
associated with the treatment as compared to total joint surgery.
Patients have been extremely satisﬁed with the results.
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Purpose: Distraction of tibio-talar joints in severe ankle os-
teoarthritis (OA) has demonstrated clinical efﬁcacy (A&R 2002;
OA&C 2005). However, failure rate is still considerable. From clin-
ical practice it was suggested that joint mobility (laxity) might
be related to clinical outcome. Therefore, patient characteristics
including joint mobility at baseline were compared to clinical out-
come of joint distraction in order to predict failure to treatment.
Methods: Data were used from an open prospective clinical study
in which 72 patients with severe (posttraumatic) OA of the tibio-
talar joint, who were considered for arthrodesis, were treated with
joint distraction. Range of Motion (R.O.M.) of the contralateral
joint, pain, functional ability, gender, and age at baseline were
correlated with clinical outcome at 5 years.
Results: Until now from all 72 patients (longest follow-up 15 years)
39% of the patients underwent arthrodesis. The patients with a
follow-up of ≥ 12 years (n=7) still showed a signiﬁcant improve-
ment of pain (-48%, p=0.04) and functional ability (+ 63%, p=0.03).
From 53 (43.8±10 years) out of the 72 patients data on R.O.M.
of the contralateral ankle joint at baseline and clinical outcome
at 5 years was available. 5 years after treatment, 31 patients
were still in follow-up while 22 patients underwent arthrodesis.
The R.O.M. of the contralateral ankle joint, pain, and functional
ability at baseline correlated with improvement of functional ability
(resp. R=0.51, R=0.27, R=0.47 p=0.003, ns, p=0.007) and pain
(resp. R=0.34, R=0.41, R=0.47, p=0.06, p=0.022, p=0.007). No
correlations were found for age and gender. However, 23% of all
male patients (n=30) underwent arthrodesis, compared to 65% of
all female patients (n=23) (p=0.002).
Conclusions: Joint distraction results in prolonged clinical beneﬁt
in the treatment of severe ankle osteoarthritis, although with a
failure rate over the years of 39%. A high R.O.M. (of the con-
tralateral healthy joint), a high pain and a low functional ability
at baseline relate to a better clinical beneﬁt of joint distraction
5 years after treatment. Interestingly, only gender predicts the
percentage arthrodeses, although the underlying mechanism is
unknown. Further evaluations on predictive parameters have to be
performed.
